Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Dose Escalation Study of JNJ-79635322 in Relapsed/Refractory Multiple Myeloma or Previously Treated AL Amyloidosis
jRCT2051240071Phase 1Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of ramantamig in multiple myeloma (MM) and light-chain amyloidosis (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Dose-limiting Toxicity (DLT), Number of Participants with Adverse Events (AEs) by Severity and 1 more. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
ramantamig
03
Conditions
multiple myeloma (MM)light-chain amyloidosis
Beyond the preview
Go deeper on jRCT2051240071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240071.